Tafinlar-Mekinist revenue trends
In 3Q17, Novartis’s (NVS) Tafinlar-Mekinist generated revenues of $224 million, which was ~30% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter).
In October 2017, the FDA (US Food and Drug Administration) granted the Tafinlar-Mekinist combination therapy a breakthrough therapy designation (or BTD) for the adjuvant treatment of individuals with stage-3 melanoma with a BRAF V600 mutation after complete resection. The FDA’s BTD was based on the results from the phase-3 Combi-ad trial, which, after 2.8 years, showed a substantial reduction in the risk of disease recurrence (53%) compared to placebo therapy.
Promacta-Revolade revenue trends
In 3Q17, Promacta-Revolade reported revenues of $227 million, which was ~35% higher YoY and 8% higher QoQ. Steady growth worldwide and the growth of the thrombopoietin class for chronic idiopathic thrombocytopenic purpura primarily attributed to the revenue growth of Revolade in 3Q17.
Votrient revenue trends
In 3Q17, Votrient generated revenues of ~$213 million, which was ~16% higher YoY and 4% higher QoQ. Sales growth in the US and the phasing in of emerging markets primarily attributed to this double-digit YoY revenue growth in 3Q17.
Votrient is indicated for the treatment of individuals with advanced renal cell carcinoma (or RCC).
In the RCC drugs market, Votrient competes with Pfizer’s (PFE) Sutent, Bristol-Myers Squibb’s (BMY) Opdivo, Bayer’s (BAYZF) Nexavar, and Roche’s Avastin. In 3Q17, Sutent, Opdivo, and Avastin reported revenues of ~$276 million, ~$1.26 billion, and ~$1.6 billion, respectively.
Notably, the Vanguard FTSE All-World ex-US ETF (VEU) invests ~0.77% of its total portfolio holdings in Novartis.